Can bupivacaine be used in subtenon blocks?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Bupivacaine Be Used in Subtenon Blocks?

Yes, bupivacaine can be safely used for subtenon blocks in ophthalmic surgery, with typical dosing of 0.25% bupivacaine at volumes of 3-5 mL (7.5-12.5 mg total), well below the maximum safe dose of 2.5 mg/kg.

Dosing Recommendations for Subtenon Blocks

  • The maximum safe dose of bupivacaine 0.25% is 2.5 mg/kg (equivalent to 1 mL/kg) for peripheral nerve blocks and local infiltration, which provides a substantial safety margin for subtenon blocks 1, 2.

  • For a typical 70 kg adult, this translates to a maximum of 175 mg (70 mL of 0.25% solution), far exceeding the 3-5 mL typically used in subtenon anesthesia 1.

  • Bupivacaine 0.25% at 0.2-0.5 mL/kg is recommended for peripheral nerve blocks, and subtenon blocks fall well within this range given their small volumes 1, 3.

Clinical Advantages in Ophthalmic Surgery

  • Bupivacaine provides long-lasting analgesia lasting 4-8 hours or longer, making it ideal for postoperative pain control after ophthalmic procedures 1.

  • The slow onset of bupivacaine (typically 10-20 minutes) is not a disadvantage in subtenon blocks, as adequate time is available before surgical incision 4.

  • Bupivacaine's sensory-motor dissociation at lower concentrations (0.25%) provides excellent analgesia with minimal motor blockade, which is desirable for maintaining extraocular muscle function 4, 5.

Alternative Local Anesthetics

  • Levobupivacaine 0.25% can be used at the same 2.5 mg/kg maximum dose and offers a potentially improved safety profile with reduced cardiac toxicity compared to racemic bupivacaine 2, 4.

  • Ropivacaine 0.2% allows up to 3 mg/kg (1.5 mL/kg), providing a higher maximum dose than bupivacaine if larger volumes are needed, though this is rarely necessary for subtenon blocks 1, 3, 4.

  • Both levobupivacaine and ropivacaine are pure left-isomers with less cardiotoxic potential than racemic bupivacaine, making them preferred choices when available 4.

Safety Considerations

  • Always calculate total dose in mg/kg, not just volume, as concentrations vary between preparations 2, 3.

  • Bupivacaine has the highest cardiotoxicity among amide local anesthetics, with risk of severe cardiac effects if inadvertent intravascular injection occurs 4, 6.

  • The small volumes used in subtenon blocks (3-5 mL) provide an inherent safety margin, as systemic toxicity typically requires much higher doses 1, 2.

  • Be prepared to manage local anesthetic systemic toxicity (LAST) with lipid emulsion therapy (1.5 mL/kg of 20% lipid emulsion) for cardiovascular collapse 2.

Common Pitfalls to Avoid

  • Do not exceed 2.5 mg/kg total dose when using bupivacaine 0.25% for any regional block 1, 2.

  • Avoid using higher concentrations (0.5% or 0.75%) for subtenon blocks, as the 0.25% concentration provides adequate anesthesia with improved safety 1, 5.

  • In elderly patients or those with significant comorbidities, consider dose reduction to minimize systemic absorption and potential toxicity 1.

References

Guideline

Dosis de Bupivacaína

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Bupivacaine Dosing for Closed Reduction of Distal Radius Fracture

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ropivacaine Dose Limits

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Bupivacaine, levobupivacaine and ropivacaine: are they clinically different?

Best practice & research. Clinical anaesthesiology, 2005

Research

Spinal analgesia with bupivacaine, mepivacaine and tetracaine.

Acta anaesthesiologica Scandinavica, 1983

Research

[Mechanisms of the cardiac toxicity of bupivacaine].

Annales francaises d'anesthesie et de reanimation, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.